

Our testing process.



Step 1

A suspicious mole was identified and a biopsy was performed. Your healthcare professional orders MyPath Melanoma or DiffDx-Melanoma.



Step 2

Castle Biosciences works with your healthcare professional's laboratory to obtain a tissue sample from your original biopsy.



Step 3

Our laboratory analyzes your tissue sample with our genomic test.



Step 4

We send your test results to your healthcare professional, so that they can discuss your individual results with you and determine next steps.

MyPath | DiffDx
►Melanoma

Patient Resource Guide

Understanding your test results
and the impact on your care.

For more information, visit:
mymelanomadiagnosis.com

CASTLE
BIOSCIENCES

Laboratory Address:
3737 N. 7th Street, Ste. 160
Phoenix, AZ 85014

CLIA-certified,
CAP-accredited
laboratory

©2022 Castle Biosciences Inc, DecisionDx® DiffDx®-Melanoma
and MyPath® Melanoma are trademarks of Castle Biosciences Inc.
dGEP-012v1-082022





How are melanocytic lesions assessed?

Your healthcare provider conducts a head-to-toe examination of your skin to identify any suspicious moles or growths. If there is concern, the mole will be removed (a skin biopsy) and sent to a dermatopathologist.

Dermatopathologists are highly trained physicians who specialize in the diagnosis of skin disorders using microscopes and laboratory tests. The dermatopathologist interprets the biopsy findings and reports them to your healthcare provider.

How does our test help guide your care?

Most moles are easily diagnosed as benign or malignant; however, even the most experienced dermatopathologists occasionally cannot be entirely certain of the diagnosis using the microscope alone.

The MyPath Melanoma or DiffDx-Melanoma test may be ordered by the dermatopathologist or dermatologist to gather additional information.

This testing analyzes the biopsy specimen at the molecular level to help determine its diagnosis. These results, along with information obtained by examining the mole under the microscope, are analyzed by healthcare providers to arrive at a more accurate diagnosis. A more accurate diagnosis will guide your healthcare provider in developing the most appropriate treatment path for you.

What do your results mean?

The test results are split into three categories: suggestive of benign, intermediate, or suggestive of malignant. This information along with all other clinical and pathological findings will assist your pathologist when rendering a diagnosis and guide your healthcare provider in developing the most appropriate treatment plan.



How is the test paid for?

Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure payment for the MyPath Melanoma and DiffDx-Melanoma tests. We will submit insurance claims and manage the billing process on behalf of patients. The company also sponsors an industry leading Patient Assistance Program with the belief that quality care should not depend on financial considerations. You can get more information about insurance coverage, claims processing and financial assistance by calling 866-788-9007 and selecting option #3 or sending an email to: reimbursement@castlebiosciences.com.